The Food and Drug Administration (FDA) has authorized the Visby Medical Women’s Sexual Health Test, the first at-home test for diagnosing 3 sexually transmitted infections (STIs) in females: chlamydia, gonorrhea, and trichomoniasis. The hope is that the option will increase the use of testing and thus help prevent transmission of these STIs. No prescription is required, and the test can be used for those with or without symptoms. Each single-use test kit includes a self-collected vaginal swab and a powered testing device that connects to a Visby app. Results are available in approximately 30 minutes in the app.
Accuracy matters: Tests correctly identified 98.8% of negative and 97.2% of positive Chlamydia trachomatis samples, 99.1% of negative and 100% of positive Neisseria gonorrhoeae samples and 98.5% of negative and 97.8% of positive Trichomonas vaginalis samples. More home tests and self-collection options have reached the market in the past 2 years, increasing choices for consumers.